Abstract:Objective To evaluate the efficacy and safety of Adefovir dipivoxil in the 52-week treatment of chronic hepatitis B in China.Methods We randomly assigned 480 patients with chronic hepatitis B who were positive for hepatitis B e antigen(HBeAg)in China.During the first 12-week period,480 patients were randomly to receive either 10 mg of adefovir dipivoxil(ADV)or placebo once daily in a 2:1 ratio and in the second period,all patients were accepted ADV for 18 weeks.In the last 12-week stage,all patients treated by ADV were randomly to receive either 10 mg of ADV or placebo in a 2:1 ratio and patients treated by placebo were accepted ADV.The primary end point was serum HBV DNA change during the treatment.The secondary endpoints were ALT normalization rate,HBeAg loss rate and HBeAg seroconversion rate.Results At week 12,median serum hepatitis B virus(HBV)DNA levels of group AAA(ADV-ADV-ADV)and group AAP(ADV-ADV-Placebo) were reduced 3.4 and 3.3 log copies per milliliter,significantly greater than group PAA(Placebo- ADV-ADV)of 0.1 log copies/ml reduction(P<0.05).At week 40,serum hepatitis B virus(HBV) DNA levels of all 3 groups were reduced 4.0～4.6 lg copies/ml.At week 52,median serum HBV DNA levels were reduced 5.0 and 4.5 log copies/ml in group PAA and AAA.Meanwhile,HBV DNA was reduced to level under detection in 30.3% and 28.4% patients of these 2 groups.However,HBV DNA level in group AAP rebound to baseline level and HBV DNA in only 0.8% patients(1/119)of this group was reduced to the level under detection.Alanine aminotransferase levels had normalized at week 52 in 69.2 percent and 78.6 percent of patients of groups PAA and AAA.Comparably.the ALT normalization rate reduced to 21.1%(23/109)at week 52 from 74.3%(81/109).HBeAg loss rate and HBeAg seroconversion rate at 52 week in group PAA were 200% and 17% compared with 13% and 8% in group AAA.However,the HBeAg loss rate and HBeAg seroconversion rate in group AAP were decreased from 14% and 11% at week 40 to 9% and 4% at week 52.No HBV polymerase mutations associated with resistance to ADV were identified.Only 5%～11% patients had at least one adverse event and most of which were mild to moderate.There were no significant differences in the changes in serum creatinine or serum phosphorus values compared with baseline level.Conclusions In Chinese patients with HBeAg-positive chronic hepatitis B,52 weeks of ADV treatment resulted in sig- nificant virologic,and biochemical improvement with good safety profile.No evidence of the emer- gence of adefoyir-resistant HBV polymerase mutations was found.

Clinical Observation on Adefovir Dipivoxil for Treating HBeAg-Positive Chronic Hepatitis B in 38 Cases

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance

The Clinical Efficacy of the Adefovir Dipivoxii in the Treatment of 36 Chronic Hepatitis B Patients with HBeAg-positive

[The Analyse of Effectiveness in HBeAg-positive Chronic Viral Hepatitis B Treated by Adefovir Dipivoxil Combined with Bicyclol].

[A Clinical Study of Adefovir Dipivoxil in Treating Lamivudine Refractory HBeAg-positive Chronic Hepatitis B].

Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B in China

A Double-Blind Randomized Trial of Adefovir Dipivoxil in Chinese Subjects with HBeAg-positive Chronic Hepatitis B

Clinical Effect of Xiaoyao Pill Auxiliary Adefovir Dipivoxil on Patients with Chronic Hepatitis B

A Randomized, Double-Blind, Multicenter Study of Adefovir Dipivoxil in Treating Patients with HBeAg-positive Chronic Hepatitis B

Efficacy of Combined Therapy in Patients with Hepatitis B Virus-Related Decompensated Cirrhosis.

Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection

Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.

Two Years Efficiency of Lamivudine and Adefovir Dipivoxil Combined Therapy in Chronic Hepatitis B Patients

PEG-Tα1 and Adefovir Dipivoxil in Patients with HBeAg-positive Chronic Hepatitis B:A phase ⅡClinical Trial

496 Efficacy and safety of 2 years adefovir dipivoxil (ADV) in chinese patients with HBeAg positive chronic hepatitis B (CHB)

Factors associated with the therapeutic effect of lamivudine-resistant chronic hepatitis B during adefovir dipivoxil therapy

Predictors of Response in Patients with HBeAg-positive Chronic Hepatitis B with Adefovir Dipivoxil Treatment

Efficacy of adefovir dipivoxil therapy in patients with chronic hepatitis B viral infection

Clinical Observation of Nucleotide Analogues in Treating Patients with Chronic Hepatitis B

A clinical study of adefovir dipivoxil, made in China, for treatment of hepatitis B e antigen-positive patients with chronic hepatitis B]